Gene therapy for color blindness
Gene therapy for color blindness is an experimental gene therapy aiming to convert congenitally colorblind individuals to trichromats by introducing a photopigment gene that they lack. Though partial color blindness is considered only a mild disability, it is a condition that affects many people, particularly males. Complete color blindness, or achromatopsia, is very rare but more severe. While never demonstrated in humans, animal studies have shown that it is possible to confer color vision by injecting a gene of the missing photopigment using gene therapy. As of 2018 there is no medical entity offering this treatment, and no clinical trials available for volunteers.
The retina of the human eye contains photoreceptive cells called cones that allow color vision. A normal trichromat individual possesses three different types of cones to distinguish different colors within the visible spectrum from 380 nm to 740 nm. The three types of cones are designated L, M, and S cones, and each type is sensitive to a certain range of wavelength of light depending on what photopigment it contains. More specifically, the L cone absorbs around 560 nm, the M cone absorbs near 530 nm, and the S cone absorbs near 420 nm. Contrary to popular belief, the peak absorption frequency for L, M, and S cones do not exactly correspond to red, green, and blue wavelength. Rather, the peak frequency for the L cone is orange, yellowish green in M cones, and blue-violet in S cones. These cones transduce the absorbed light into electrical information to be relayed to neurons in the retina such as retinal bipolar cells and retinal ganglion cells, before reaching the brain.
The signals from different cones are added or subtracted from each other to process the color of incoming light. For instance, the color red stimulate L cones more than M cones, whereas the color green stimulates the L and M cones more than the S cones. The colors are perceived in an opponent process, such that red and green are perceived in opposition, as are blue and yellow, black and white.
The gene loci coding for the photopigments: M-opsin and L-opsin are located in close proximity within the X chromosome and are highly polymorphic. Among the population, some have a deleted gene for the M photopigment in the X chromosome (such as in deuteranopia), whereas others have a mutated form of the gene (such as in deuteranomaly). Individuals who can express only two types of opsins in the cones are called dichromats. Because males have only one copy of the X chromosome, dichromatism is much more prevalent among men. With only two types of cones, dichromats are less capable of distinguishing between two colors. In the most common form of color blindness, deuteranopes have difficulty discriminating between red and green color. This is shown by their poor performance in Ishihara test. Although dichromatism poses little problem for daily life, dichromats may find some color-coded diagrams and maps difficult to read.
Less common forms of dichromacy include protoanopia (lack of L-cones), and tritanopia (lack of S-cones). If a person lacks two types of photopigments, they are considered monochromats. People lacking the three types of photopigments are said to have complete color blindness or achromatopsia. Color blindness can also result from damages to the visual cortex in the brain.
Experiments using a variety of mammals (including primates) demonstrated that it is possible to confer color vision to animals by introducing an opsin gene that the animal previously lacked. Using a replication-defective recombinant adeno-associated virus (rAAV) as a vector, the cDNA of the opsin gene found in the L or M cones can be delivered to some fraction of the cones within the retina via subretinal injection. Upon gaining the gene, the cone begins to express the new photopigment. The effect of therapy lasts until the cones die or the inserted DNA is lost within the cones.
While gene therapy for humans has been ongoing with some success, a gene therapy for humans to gain color vision has not been attempted to date. However, demonstrations using several mammals (including primates such as a squirrel monkey) suggest that the therapy should be feasible for humans as well. It is also theoretically possible for trichromats to be "upgraded" to tetrachromats by introducing new opsin genes.
The goal of the gene therapy is to make some of the cones in the retina of a dichromat individual to express the missing photopigment. Although partial color blindness is considered to be a mild disability and even an advantage under certain circumstances (such as spotting camouflaged objects), it can pose challenges for many occupational fields such as law enforcement, aviation, railroad, and military service. More generally, color codes in maps and figures may be difficult to read for individuals with color blindness.
Because only a single gene codes for a photopigment and the gene is only expressed in the retina, it is a relatively easy condition to treat using gene therapy compared to other genetic diseases. However, there remains the question of whether the therapy is worthwhile, for an individual to undergo an invasive subretinal injection to temporarily treat a condition that is more of an inconvenience than a disorder.
However, complete color blindness, or achromatopsia, is very rare but more severe. Indeed, achromats cannot see any color, have a strong photophobia (blindness in full sun), and a reduced visual acuity (generally 20/200 after correction).
Moreover, the research may have strong implications toward genetic therapy of other cone diseases. Other cone diseases such as Leber's congenital amaurosis, cone-rod dystrophy, and certain types of maculopathies may be treatable using the same techniques as the gene therapy used for color blindness.
Research so farEdit
There has been ongoing research for gene therapy to treat Leber's congenital amaurosis, a genetic disorder in photoreceptors that can lead to vision loss and blindness. These treatments use AAV vector and is delivered in much the same way as the gene therapy for color blindness.
Jacobs et al. published their research in the journal: Science in 2007, on their work introducing a human L-cone photopigment in mice. Since the mice possess only S cones and M cones, they are dichromats. The researchers replaced M-opsin with a cDNA of L-opsin in the X chromosome of some mice. By breeding these "knock-in" transgenic mice, they generated heterozygous females with both an M cone and an L cone. These mice had improved range of color vision and have gained trichromacy, as tested by electroretinogram and behavioral tests. However, this is more difficult to apply in the form of gene therapy.
In a paper published in the journal: Visual Neuroscience by Mauck et al., researchers used recombinant AAV vector to introduce the green fluorescent protein (GFP) gene in the cones of gerbils. The genetic insert was designed to only be expressed in S or M cones, and the study observed the expression of GFP in vivo over time. The study characterized the time of onset of expression, and also demonstrated that gene expression could stabilize if a sufficiently high dose of the viral vector is given.
Mancuso et al. published their research in the journal: Nature in 2009, on converting adult dichromat squirrel monkeys into trichromats using gene therapy. New world monkeys such as squirrel monkeys lack the L-opsin gene and are incapable of discriminating between certain shades of red and green. The researchers used recombinant AAV vector to deliver a human L-opsin gene into the monkey’s retina. Cones that gained the missing genes began expressing the new photopigment.
The researchers raised two possibilities if the therapy worked—that the monkeys would either remain dichromatic with greater sensitivity for longer wavelength of light, or they would become trichromats. Electroretinogram recordings demonstrated that they are able to discriminate blue-green from red-violet, and have indeed gained trichromacy. The treated monkeys were also more successful when their color vision was tested with a modified Ishihara test.
In 2007, Alexander JJ et al. used gene therapy to restore some of the sight of mice with achromatopsia. The results were positive for 80% of the mice treated. Moreover, a paper by Komáromy et al., published in 2010, deals with gene therapy for a form of achromatopsia in dogs. Cone function and day vision have been restored for at least 33 months in two young dogs with achromatopsia. However, this therapy was less efficient for older dogs.
According to research by David H. Hubel and Torsten Wiesel, suturing shut one eye of monkeys at an early age resulted in an irreversible loss of vision in that eye, even after the suture was removed. The study concluded that the neural circuitry for vision is wired during a "critical period" in childhood, after which the visual circuitry can no longer be rewired to process new sensory input. Contrary to this finding, Mancuso et al.’s success in conferring trichromacy to adult squirrel monkeys suggests that it is possible to adapt the preexisting circuit to allow greater acuity in color vision. The researchers concluded that integrating the stimulus from the new photopigment as an adult was not analogous to vision loss following visual deprivation.
It is yet unknown how the animals that gain a new photopigment are perceiving the new color. While the article by Mancuso et al. states that the monkey has indeed gained trichromacy and gained the ability to discriminate between red and green, they claim no knowledge of how the animal internally perceives the sensation.
While red/green color blindness among deuteranopes can be treated by introducing M-opsin genes, rarer forms of color blindness such as tritanopia can in principle be treated as well. For tritanopia, the S-opsin gene must be introduced instead of M-opsin gene.
Despite the success in animals, there still remain challenges to conducting gene therapy on humans for treating color blindness.
How to deliver the viral vector into the retina is probably the main obstacle to making gene therapy a practical treatment for color blindness. Because the virus has to be injected directly by using a needle to penetrate the sclera of the eye, the treatment may be highly unpleasant and is a risk for eye infection. Without a way to deliver the virus noninvasively, the treatment is rather risky for the benefit gained.
It is not known yet how frequently the gene needs to be injected to maintain trichromacy among congenitally colorblind individuals. At the time of publication, Mancuso et al. reports that the treated squirrel monkeys have maintained 2 years of color vision after the treatment. If repeat injections are needed, there is also the concern of the body developing an immune reaction to the virus. If a body develops sensitivity to the viral vector, the success of the therapy could be jeopardized and/or the body may respond unfavorably. An editorial by J. Bennett points to Mancuso et al.'s use of an "unspecified postinjection corticosteroid therapy". Bennett suggests that the monkeys may have experienced inflammation due to the injection. However, the AAV virus that is commonly used for this study is non-pathogenic, and the body is less likely to develop an immune reaction. Needless to say, an extensive review of the safety of the treatment must precede any human trials.
The subject should first be evaluated to identify which photopigment they need to gain trichromacy. Also, while gene therapy may treat congenital color blindness (such as dichromacy), it is not intended to treat non-retinal forms of color blindness such as damage to the visual cortex of the brain.
As a way to introduce new genetic information to change a person’s phenotype, a gene therapy for color blindness is open to the same ethical questions and criticisms as gene therapy in general. These include issues around the governance of the therapy, whether treatment should be available only to those who can afford it, and whether the availability of treatment creates a stigma for those with color blindness. Given the large number of people with color blindness, there is also the question of whether color blindness is a disorder. Furthermore, even if gene therapy succeeds in converting incomplete colorblind individuals to trichromats, the degree of satisfaction among the subjects is unknown. It is uncertain how the quality of life will improve (or worsen) after the therapy.
- Kandel ER, Schwartz JH, Jessel TM, eds. (2000). "Ch. 29: Color Vision". Principles of Neural Science. McGraw-Hill Professional. ISBN 978-0-8385-7701-1.CS1 maint: uses editors parameter (link)
- "Colour blindness treatment". World Eye Centers Istanbul. Archived from the original on 2009-06-18. Retrieved 2009-07-05. Cite uses deprecated parameter
- Pang, J.-J., J. Alexander, et al. (2010). Achromatopsia as a Potential Candidate for Gene Therapy: 639-646.
- Bennett J. Gene Therapy for Color Blindness. N Engl J Med. 17 December 2009, 2009;361(25):2483-4.
- Bennicelli, J., J. F. Wright, et al. (2008). "Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer." Mol Ther 16(3): 458-465.
- Jacobson, S. G. B., Sanford L.; Aleman, Tomas S.; Thomas J. Conlon, Caroline J. Zeiss, Alejandro J. Roman, Artur V. Cideciyan, Sharon B. Schwartz, Andras M. Komaromy, Michelle Doobrajh, Andy Y. Cheung, Alexander Sumaroka, Susan E. Pearce-Kelling, Gustavo D. Aguirre, Shalesh Kaushal, Albert M. Maguire, Terence R. Flotte, William W. Hauswirth. (2006). "Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital Amaurosis." Human Gene Therapy 17(8).
- Jacobs, G. H., G. A. Williams, et al. (2007). "Emergence of Novel Color Vision in Mice Engineered to Express a Human Cone Photopigment." Science 315(5819): 1723-1725.
- Mauck, M. C., K. Mancuso, et al. (2008). "Longitudinal evaluation of expression of virally delivered transgenes in gerbil cone photoreceptors." Visual Neuroscience 25(03): 273-282.
- Mancuso, K., W. W. Hauswirth, et al. (2009). "Gene therapy for red‚ and green colour blindness in adult primates." Nature 461(7265): 784-787.
- Alexander JJ, et al. (2007). "Restoration of cone vision in a mouse model of achromatopsia." Nat. Med. Jun;13(6):685-7. Epub 21 May 2007.
- Komáromy, K., et al. (2010). "Gene therapy rescues cone function in congenital achromatopsia." Human Molecular Genetics doi:10.1093/hmg/ddq136 .
- D. H. Hubel, T. N. Wiesel, and S. LeVay. Plasticity of Ocular Dominance Columns in Monkey Striate CortexPhil. Trans. R. Soc. Lond. B April 26, 1977 278:377-409; doi:10.1098/rstb.1977.0050
- Grieger JC, Samulski RJ (2005). "Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications". Advances in Biochemical Engineering/biotechnology 99: 119–45. doi:10.1007/10_005. PMID 16568890
- Morgan MJ, Adam A, Mollon JD. "Dichromats detect colour-camouflaged objects that are not detected by trichromats." Proc Biol Sci. 22 June 1992;248 (1323):291-5. PMID 1354367.